Dr. Gandhi Discusses the Role of Alectinib in ALK+ Lung Cancer

In Partnership With:

Partner | Cancer Centers | <b>NYU Langone's Perlmutter Cancer Center</b>

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non-small cell lung cancer (NSCLC).

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non—small cell lung cancer (NSCLC).

Gandhi says that there is clear-cut evidence of the superiority of alectinib over crizotinib (Xalkori). Results from the J-ALEX and ALEX trials showed improved long-term outcomes systemically with alectinib, and in the central nervous system (CNS), as well.